Dexmecamylamine
As of the edition of 20 October 2026, Dexmecamylamine is a small molecule: went quiet in 2021; acts on CHRNA4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Small molecule
- Registered trials
- 19, 5 stopped early
- Disease areas
- Mental health; Pregnancy and women's health; Urinary and reproductive; Chemically induced; Heart and blood vessels; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA4 | Neuronal acetylcholine receptor subunit alpha-4 | P43681 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 9 | 6 | 0 | 3 |
| Phase 2 | 5 | 2 | 0 | 2 |
| Phase 3 | 5 | 5 | 0 | 0 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Targacept | Lead sponsor of trials | 2009 to now |
| AstraZeneca | Lead sponsor of trials | 2010 to now |
| Atacama Therapeutics | Lead sponsor of trials | 2017 to now |